Plus Therapeutics (PSTV) News Today $0.50 -0.12 (-19.41%) Closing price 05/6/2025 04:00 PM EasternExtended Trading$0.52 +0.02 (+3.02%) As of 05:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period D. Boral Capital Reaffirms "Hold" Rating for Plus Therapeutics (NASDAQ:PSTV)May 7 at 1:59 AM | americanbankingnews.comD. Boral Capital Downgrades Plus Therapeutics (PSTV)May 5 at 6:18 PM | msn.comPlus Therapeutics appoints Kyle Guse to board of directorsApril 23, 2025 | markets.businessinsider.comPlus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of DirectorsApril 23, 2025 | globenewswire.comPlus Therapeutics Appoints Kyle Guse to BoardApril 18, 2025 | tipranks.comPlus Therapeutics presents data highlighting clinical benefit, safety of REYOBIQApril 16, 2025 | markets.businessinsider.comPlus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal MetastasesApril 15, 2025 | globenewswire.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comPlus Therapeutics price target lowered to $5.50 from $8 at H.C. WainwrightMarch 29, 2025 | markets.businessinsider.comPlus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timelineMarch 28, 2025 | msn.comPlus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comPlus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 27, 2025 | globenewswire.comWhy Plus Therapeutics Is Rising In Pre-market?March 22, 2025 | nasdaq.comPlus Therapeutics announces FDA conditionally accepted name REYOBIQMarch 21, 2025 | markets.businessinsider.comWhy Plus Therapeutics Inc. (PSTV) Surged On Thursday?March 21, 2025 | msn.comPlus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug CandidateMarch 20, 2025 | globenewswire.comPlus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025March 19, 2025 | globenewswire.comD. Boral Capital Initiates Coverage of Plus Therapeutics (PSTV) with Buy RecommendationMarch 18, 2025 | msn.comPlus Therapeutics initiated with a Buy at D. Boral CapitalMarch 17, 2025 | markets.businessinsider.comD. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. in Connection with its up to $15.0 Million Private PlacementMarch 11, 2025 | finanznachrichten.dePlus regains compliance with Nasdaq minimum stockholders’ equity requirementMarch 10, 2025 | markets.businessinsider.comPlus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity RequirementMarch 10, 2025 | finance.yahoo.comPlus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementMarch 10, 2025 | globenewswire.comPlus Therapeutics Stock Price, Quotes and ForecastsMarch 7, 2025 | benzinga.comPlus Therapeutics announces publication of results on 186Re ObisbemedaMarch 7, 2025 | markets.businessinsider.comPlus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in GlioblastomaMarch 7, 2025 | globenewswire.comPlus Therapeutics granted Orphan Drug Designation for Rhenium ObisbemedaMarch 6, 2025 | markets.businessinsider.comPlus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatmentMarch 6, 2025 | msn.comPlus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung CancerMarch 6, 2025 | globenewswire.comPlus Therapeutics Announces New Employment Inducement GrantsMarch 5, 2025 | globenewswire.comPlus Therapeutics sees $15M in gross proceeds from private placementMarch 4, 2025 | markets.businessinsider.comPlus Therapeutics Secures Private Placement of Approximately $15 Million in Gross ProceedsMarch 4, 2025 | globenewswire.comPlus Therapeutics granted orphan designation for lung cancer treatmentMarch 1, 2025 | markets.businessinsider.comPlus Therapeutics advances Rhenium ObisbemedaFebruary 27, 2025 | markets.businessinsider.comPlus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal MetastasesFebruary 26, 2025 | globenewswire.comPlus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics SubsidiaryFebruary 24, 2025 | markets.businessinsider.comPlus Therapeutics appoints Russell Bradley as president, CNSideFebruary 24, 2025 | markets.businessinsider.comPlus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics SubsidiaryFebruary 24, 2025 | globenewswire.comPlus Therapeutics apoints Michael Rosol as Chief Development OfficerFebruary 20, 2025 | markets.businessinsider.comPlus Therapeutics Appoints Dr. Michael Rosol as Chief Development OfficerFebruary 20, 2025 | globenewswire.comPlus Therapeutics secures $5.7M financingFebruary 19, 2025 | markets.businessinsider.comPlus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases ProgramFebruary 18, 2025 | globenewswire.comPlus Therapeutics presented data on ReSPECT-LM Phase 1 trialDecember 18, 2024 | markets.businessinsider.comPlus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer SymposiumDecember 17, 2024 | globenewswire.comPlus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer SymposiumDecember 4, 2024 | globenewswire.comPlus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope SupplyDecember 3, 2024 | globenewswire.comPlus Therapeutics presents updated progress from its ReSPECT-LM Phase 1 trialNovember 27, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Diagnostic Innovations Drive Buy Rating for Plus TherapeuticsNovember 27, 2024 | markets.businessinsider.comPlus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual ConferenceNovember 25, 2024 | globenewswire.comPlus Therapeutics to present FORESEE clinical trial summaryNovember 23, 2024 | markets.businessinsider.com Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address PSTV Media Mentions By Week PSTV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTV News Sentiment▼-0.670.69▲Average Medical News Sentiment PSTV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTV Articles This Week▼42▲PSTV Articles Average Week Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Modular Medical News Today TELA Bio News Today Baird Medical Investment News Today BioSig Technologies News Today Daxor News Today Precision Optics News Today Femasys News Today Spectral AI News Today NeuroOne Medical Technologies News Today Envoy Medical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTV) was last updated on 5/7/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
